
News|Articles|June 10, 2026
Q&A: How Specialty Pharmacies Are Evolving Into Disease Management Hubs
Specialty pharmacies are moving beyond the dispense—layering SDOH screening, adherence coaching, and chronic disease management into the patient journey.
Advertisement
Advertisement
For decades, the specialty pharmacy's core value proposition was straightforward: get a complex, high-cost medication into the hands of the right patient at the right time. That mission remains essential, but as the financial and clinical stakes of specialty therapeutics escalate, a growing number of health system specialty pharmacies are pushing past the dispense model, positioning themselves as longitudinal care partners embedded in the clinical workflow.
Related to this article

At LogiPharma USA 2026, Cold Chain Technologies' TJ Rizzo explains how gaps in end-to-end cold chain expertise create risk for advanced therapies.

Octapharma USA's Kerem Tokel explains how tariffs and DSCSA are affecting how stolen pharma loads are resold, and why partner SOPs matter.

At LogiPharma USA 2026, Mark Talens explains where pharma gains the most from shared distribution visibility.

In this week's Pharma Pulse, PhRMA sues to block CMS's GLOBE pricing model, WFS opens a temperature-controlled cargo terminal in Lyon and Bayer commits $2.2 billion to a new Ohio manufacturing site.

Freehand CEO Nitin Jayakrishnan explains why pharma manufacturers are trading long-term plans for operating models built to sense and pivot.

PhRMA's lawsuit argues CMS overstepped its demonstration authority by tying Medicare Part B rebates to international prices.

At LogiPharma USA 2026, Swisslog's Garrett Freeman explains how onshoring, geopolitical risk and a shifting product mix are driving supply chain automation.
Advertisement
Advertisement

